Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16823395 | 1.00 | KDM4E (0.72) | KDM4EMAPTALDH1A1KMT2ANPC1 | |
| SCHEMBL12720844 | 0.84 | KDM4E (0.66) | KDM4EMAPTALDH1A1KMT2ANPC1 | |
| SCHEMBL12720904 | 0.81 | MAPT (0.60) | KDM4EMAPTALDH1A1KMT2ANPC1 | |
| SCHEMBL19736410 | 0.80 | KDM4E (0.64) | KDM4EMAPTALDH1A1KMT2ANPC1 | |
| SCHEMBL26053956 | 0.77 | KMT2A (0.53) | KDM4EMAPTALDH1A1KMT2ANPC1 | |
| SCHEMBL22764889 | 0.76 | SLC40A1 (0.55) | KDM4EMAPTALDH1A1KMT2ANPC1 | |
| SCHEMBL29044134 | 0.76 | KDM4E (0.60) | KDM4EMAPTALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL6721105 | 0.75 | KDM4E (0.77) | KDM4EMAPTALDH1A1KMT2ANPC1 | |
| Salinazid SCHEMBL564002 | 0.75 | NPC1 (1.00) | KDM4EMAPTALDH1A1KMT2ANPC1 | |
| Salinazid SCHEMBL29444172 | 0.75 | NPC1 (1.00) | KDM4EMAPTALDH1A1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600701-B2 | N-acylhydrazonic compounds, use in the treatment of amyloid and non-amyloid degenerative aggregopathies, and pharmaceutical composition | FACULDADES CATÓLICAS (BR) | 2026-04-14 | — | — | US | disclosed |
| US-20250197371-A1 | N-ACYLHYDRAZONIC COMPOUNDS, USE IN THE TREATMENT OF AMYLOID AND NON-AMYLOID DEGENERATIVE AGGREGOPATHIES, AND PHARMACEUTICAL COMPOSITION | FACULDADES CATÓLICAS (BR) | 2025-06-19 | — | — | US | disclosed |
| US-20230134773-A1 | N-ACYLHYDRAZONIC COMPOUNDS, USE IN THE TREATMENT OF AMYLOID AND NON-AMYLOID DEGENERATIVE AGGREGOPATHIES, AND PHARMACEUTICAL COMPOSITION | FACULDADES CATÓLICAS (BR) | 2023-05-04 | — | — | US | disclosed |
| EP-4122921-A1 | N-ACYL-HYDRAZONE COMPOUNDS, USE IN THE TREATMENT OF AMYLOID AND NON-AMYLOID DEGENERATIVE AGGREGOPATHIES, AND PHARMACEUTICAL COMPOSITION | Faculdades Católicas (BR) | 2023-01-25 | — | — | EP | disclosed |
| WO-2015089599-A1 | METHOD FOR PREPARING THE ANHYDROUS CRYSTALLINE FORM OF ISONIAZID-DERIVED HYDRAZONE, THUS PRODUCED CRYSTALLINE POLYMORPH OF THE ANHYDROUS FORM, USE THEREOF FOR THE TREATMENT OF ALZHEIMER'S DISEASE, PARKINSONISM AND OTHER NEURODEGENERATIVE DISORDERS, AND PHARMACEUTICAL COMPOSITION | FACULDADES CATÓLICAS, ASSOCIAÇÃO SEM FINS LUCRATIVOS, MANTENEDORA DA PONTIFÍCIA UNIVERSIDADE CATÓLICA (BR) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600701-B2 | N-acylhydrazonic compounds, use in the treatment of amyloid and non-amyloid degenerative aggregopathies, and pharmaceutical composition | IAPP, APBA1, TTR | KDM4E 2581/4885MAPT 27/4885ALDH1A1 2929/4885 |
| US-20230134773-A1 | N-ACYLHYDRAZONIC COMPOUNDS, USE IN THE TREATMENT OF AMYLOID AND NON-AMYLOID DEGENERATIVE AGGREGOPATHIES, AND PHARMACEUTICAL COMPOSITION | IAPP, UACA, APBA1 | KDM4E 2989/4885MAPT 38/4885ALDH1A1 2353/4885 |
| US-20250197371-A1 | N-ACYLHYDRAZONIC COMPOUNDS, USE IN THE TREATMENT OF AMYLOID AND NON-AMYLOID DEGENERATIVE AGGREGOPATHIES, AND PHARMACEUTICAL COMPOSITION | IAPP, UACA, APBA1 | KDM4E 2904/4885MAPT 34/4885ALDH1A1 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.